150 related articles for article (PubMed ID: 6272630)
1. Aminoglycoside phosphotransferase-II-mediated amikacin resistance in Escherichia coli.
Bongaerts GP; Kaptijn GM
Antimicrob Agents Chemother; 1981 Sep; 20(3):344-50. PubMed ID: 6272630
[TBL] [Abstract][Full Text] [Related]
2. High-level amikacin resistance in Escherichia coli due to phosphorylation and impaired aminoglycoside uptake.
Perlin MH; Lerner SA
Antimicrob Agents Chemother; 1986 Feb; 29(2):216-24. PubMed ID: 2424366
[TBL] [Abstract][Full Text] [Related]
3. Amikacin resistance associated with a plasmid-borne aminoglycoside phosphotransferase in Escherichia coli.
Perlin MH; Lerner SA
Antimicrob Agents Chemother; 1979 Nov; 16(5):598-604. PubMed ID: 393165
[TBL] [Abstract][Full Text] [Related]
4. Decreased susceptibility to 4'-deoxy-6'-N-methylamikacin (BB-K311) conferred by a mutant plasmid in Escherichia coli.
Perlin MH; Lerner SA
Antimicrob Agents Chemother; 1982 Jul; 22(1):78-82. PubMed ID: 6289743
[TBL] [Abstract][Full Text] [Related]
5. Aminoglycoside-phosphotransferases APH(3')-IV and APH(3") synthesized by a strain of Campylobacter coli.
Rivera MJ; Castillo J; Martin C; Navarro M; Gomez-Lus R
J Antimicrob Chemother; 1986 Aug; 18(2):153-8. PubMed ID: 3019983
[TBL] [Abstract][Full Text] [Related]
6. Characterization of transposon Tn1528, which confers amikacin resistance by synthesis of aminoglycoside 3'-O-phosphotransferase type VI.
Lambert T; Gerbaud G; Courvalin P
Antimicrob Agents Chemother; 1994 Apr; 38(4):702-6. PubMed ID: 8031033
[TBL] [Abstract][Full Text] [Related]
7. Resistance to antibiotic synergism in Streptococcus faecalis: further studies with amikacin and with a new amikacin derivative, 4'-deoxy, 6'-N-methylamikacin.
Calderwood SB; Wennersten C; Moellering RC
Antimicrob Agents Chemother; 1981 Apr; 19(4):549-55. PubMed ID: 6264851
[TBL] [Abstract][Full Text] [Related]
8. High-level amikacin resistance in Pseudomonas aeruginosa associated with a 3'-phosphotransferase with high affinity for amikacin.
Torres C; Perlin MH; Baquero F; Lerner DL; Lerner SA
Int J Antimicrob Agents; 2000 Aug; 15(4):257-63. PubMed ID: 10929874
[TBL] [Abstract][Full Text] [Related]
9. Purification, characterization, and investigation of the mechanism of aminoglycoside 3'-phosphotransferase type Ia.
Siregar JJ; Miroshnikov K; Mobashery S
Biochemistry; 1995 Oct; 34(39):12681-8. PubMed ID: 7548020
[TBL] [Abstract][Full Text] [Related]
10. The major aminoglycoside-modifying enzyme AAC(3)-II found in Escherichia coli determines a significant disparity in its resistance to gentamicin and amikacin in China.
Xiao Y; Hu Y
Microb Drug Resist; 2012 Feb; 18(1):42-6. PubMed ID: 22066787
[TBL] [Abstract][Full Text] [Related]
11. Localization of an amikacin 3'-phosphotransferase in Escherichia coli.
Perlin MH; Lerner SA
J Bacteriol; 1981 Aug; 147(2):320-5. PubMed ID: 6267007
[TBL] [Abstract][Full Text] [Related]
12. Plasmid-medicated aminoglycoside phosphotransferase of broad substrate range that phosphorylates amikacin.
Courvalin P; Davies J
Antimicrob Agents Chemother; 1977 Apr; 11(4):619-24. PubMed ID: 856013
[TBL] [Abstract][Full Text] [Related]
13. Directed evolution of aminoglycoside phosphotransferase (3') type IIIa variants that inactivate amikacin but impose significant fitness costs.
Kramer JR; Matsumura I
PLoS One; 2013; 8(10):e76687. PubMed ID: 24204655
[TBL] [Abstract][Full Text] [Related]
14. New aminoglycoside-modifying enzymes APH(3')-VIII and APH(3')-IX in Acinetobacter rudis and Acinetobacter gerneri.
Yoon EJ; Grillot-Courvalin C; Courvalin P
J Antibiot (Tokyo); 2017 Apr; 70(4):400-403. PubMed ID: 27965516
[TBL] [Abstract][Full Text] [Related]
15. Isolation, characterization, and cloning of a plasmid-borne gene encoding a phosphotransferase that confers high-level amikacin resistance in enteric bacilli.
Gaynes R; Groisman E; Nelson E; Casadaban M; Lerner SA
Antimicrob Agents Chemother; 1988 Sep; 32(9):1379-84. PubMed ID: 2848443
[TBL] [Abstract][Full Text] [Related]
16. Isomeric DNA ladder formation of a plasmid encoding tobramycin resistance from Escherichia coli.
Singh M; John JF
J Antimicrob Chemother; 1991 Nov; 28(5):627-37. PubMed ID: 1685732
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
Saavedra S; Vera D; RamÃrez-Ronda CH
Am J Med; 1986 Jun; 80(6B):65-70. PubMed ID: 3014877
[TBL] [Abstract][Full Text] [Related]
18. Isolation and characterization of mutants of Escherichia coli K12 resistant to the new aminoglycoside antibiotic, amikacin.
Hull R; Klinger JD; Moody EE
J Gen Microbiol; 1976 Jun; 94(2):389-94. PubMed ID: 781182
[TBL] [Abstract][Full Text] [Related]
19. Tuning the regioselectivity of the Staudinger reaction for the facile synthesis of kanamycin and neomycin class antibiotics with N-1 modification.
Li J; Chen HN; Chang H; Wang J; Chang CW
Org Lett; 2005 Jul; 7(14):3061-4. PubMed ID: 15987205
[TBL] [Abstract][Full Text] [Related]
20. Structure-function analyses for aminoglycoside 3'-phosphotransferase II (APH(3')-II).
Kocabiyik S; Mullins C; Breeding C; Perlin MH
SAAS Bull Biochem Biotechnol; 1992 Jan; 5():58-63. PubMed ID: 1369370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
